Meeting
2016 Genitourinary Cancers Symposium
Chemotherapy in metastatic hormone-naïve prostate cancer: Pooled analysis of randomized clinical trials.
Authors
Paolo Fabbri
Infermi Hospital, Rimini, Italy
Paolo Fabbri , Lucia Stocchi , Stefania Nicoletti , Fabrizio Drudi , Emiliano Tamburini , Mario Nicolini , Lorenzo Gianni , Giuseppe Pasini , Francesco Montanari , Davide Tassinari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 259)
DOI
10.1200/jco.2016.34.2_suppl.259
Abstract #
259
Poster Bd #
L8
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Upfront docetaxel with androgen deprivation therapy in the elderly patient with metastatic hormone-naïve prostate cancer: Single institution experience.
First Author: Lindsay Jennifer Andrew Rayner
Poster
2022 ASCO Annual Meeting
Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.
First Author: Deniz Can Guven
Poster
2018 Genitourinary Cancers Symposium
Activity of VERU-111, an novel oral α and β tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer.
First Author: Robert H. Getzenberg
Poster
2018 Genitourinary Cancers Symposium
Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).
First Author: Jacob A Gordon